Asset Acquisitions and Disposals::Approval for negotiation for a potential acquisition of a specialty pharma business in US

Issuer & Securities

Issuer/ Manager
JUBILANT PHARMA LIMITED
Securities
JUBILANTP US$300M4.875%N211006 - XS1493722299 - 4X7B
Stapled Security
No

Announcement Details

Announcement Title
Asset Acquisitions and Disposals
Date &Time of Broadcast
21-Mar-2017 18:22:33
Status
New
Announcement Sub Title
Approval for negotiation for a potential acquisition of a specialty pharma business in US
Announcement Reference
SG170321OTHRH6MY
Submitted By (Co./ Ind. Name)
Arun Sharma
Designation
CFO-Pharma
Effective Date and Time of the event
21/03/2017 17:00:00
Description (Please provide a detailed description of the event in the box below)
The Board of Directors of Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore, has approved to negotiate a potential acquisition of a specialty pharma business in the United States using internal accruals, subject to due diligence, satisfactory agreements, etc. and its final approval. The proposed acquisition is a niche, profitable specialty pharma business with a strategic fit and is expected to provide competitive edge for JPL's existing business, if it materializes.

Attachments

Pharma_Intimation.pdf
Total size =414K